Open Journal Systems

Redefining advances in modern oncology research

Kwong-Kwok Wong ()


I am excited to be the new Editor-in-Chief of Advances in Modern Oncology Research and would like to thank the founding Editor-in-Chief, Dr. Omar Abdel Rahman, for his diligent service to the journal since its inception in 2015. AMOR, the abbreviation commonly used for the journal means “love” in Spanish. As an Open Access journal, I hope that AMOR will be a global platform to disseminate knowledge in modern oncology research from both basic and clinical scientists with a passion to find a cure for cancer.


oncology; research; targeted therapy

Full Text:



Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674. doi: 10.1016/j.cell.2011.02.013.

DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv 2016; 2(5): e1600200. doi: 10.1126/sciadv.1600200.

Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, et al. Targeting cancer metabolism: Dietary and pharmacologic interventions. Cancer Discov 2016; 6(12): 1315-1333. doi: 10.1158/2159-8290.CD-16-0615.

Ledford H. End of cancer-genome project prompts rethink. Nature 2015; 517(7533): 128-129. doi: 10.1038/517128a.

The Cancer Genome Atlas [Internet]. National Institutes of Health (US); [updated 2017 Feb 2; cited 2017 Feb 15]. Available from:

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375(22): 2154-2164. doi: 10.1056/NEJMoa1611310.

Wheler JJ, Janku F, Naing A, Li Y, Stephen B, et al. Cancer therapy directed by comprehensive genomic profiling: A single center study. Cancer Res 2016; 76(13): 3690-3701. doi: 10.1158/0008-5472.CAN-15-3043.

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375(19): 1845-1855. doi: 10.1056/NEJMoa1611299.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315(15): 1600-1609. doi: 10.1001/jama.2016.4059.

Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387(10027): 1540-1550. doi: 10.1016/S0140-6736(15)01281-7.

Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. Lancet Oncol 2017; 18(2): 212-220. doi: 10.1016/S1470-2045(17)30007-4.

U.S. Food and Drug Administration [Internet]. Silver Spring (MD): [updated 2017 Feb 2; cited 2017 Feb 15]. Available from:

Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, et al. Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-05): 1-30.

Wojtowicz ME, Dunn BK, Umar A. Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. Semin Oncol 2016; 43(1): 161-172. doi: 10.1053/j.seminoncol.2015.11.001.

Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res (Phila) 2016; 9(1): 2-10. doi: 10.1158/1940-6207.CAPR-15-0406.

Epstein AS, Prigerson HG, O'Reilly EM, Maciejewski PK. Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol 2016; 34(20): 2398-2403. doi: 10.1200/JCO.2015.63.6696.

Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016; 6(5): 479-491. doi: 10.1158/2159-8290.CD-15-1483.

Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 2015; 9(4): 783-790. doi: 10.1016/j.molonc.2014.12.003.

Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497(7447): 108-112. doi: 10.1038/nature12065.

Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 2015; 90(3): 509-515. doi: 10.1016/j.lungcan.2015.10.004.

U.S. Food and Drug Administration. Silver Spring (MD): [updated 2017 Feb 2; cited 2017 Feb 15]. Available from:

Grossman RL, Abel B, Angiuoli S, Barrett JC, Bassett D, et al. Collaborating to compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium. Clin Pharmacol Ther 2017. doi: 10.1002/cpt.666.

McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7(2): 418-419. doi: 10.3945/an.116.012211.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 2015; 35 Suppl:S276-304. doi: 10.1016/j.semcancer.2015.09.007.



  • There are currently no refbacks.

Copyright (c) 2018 Kwong-Kwok Wong

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.